Romiplostim Prevents Chemotherapy Dose Reductions in Gastrointestinal Cancers

Chemotherapy-induced thrombocytopenia remains a frequent complication of systemic cancer treatment, particularly for patients receiving oxaliplatin-based regimens for gastrointestinal malignancies [1]. When platelet counts drop precipitously, clinicians are routinely forced to delay treatment cycles or reduce chemotherapy doses, which compromises relative dose intensity and worsens oncologic outcomes [2, 1]. While thrombopoietin receptor agonists (agents that stimulate bone marrow megakaryocytes to produce platelets) like romiplostim are well-established for immune thrombocytopenia, their role in managing chemotherapy-induced platelet deficits has historically relied on limited data from single-arm studies and meta-analyses [3, 4]. Although recent clinical guidelines support considering these agents to maintain platelet counts during treatment [5, 4], high-quality randomized data confirming their ability to prevent chemotherapy dose modifications have been lacking. A recent study now offers fresh insights into the use of romiplostim for preserving scheduled cytotoxic regimens in patients with gastrointestinal cancers [6].